Experienced in Median Arcuate Ligament Syndrome (MALS)

Ulf P. Neumann

Essen, NW, DE 
Experienced in Median Arcuate Ligament Syndrome (MALS)
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Ulf Neumann practices in Essen, Germany. Neumann is rated as an Experienced expert by MediFind in the treatment of Median Arcuate Ligament Syndrome (MALS). Their top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Muscle Atrophy, Liver Transplant, and Hepatectomy.

Their clinical research consists of co-authoring 423 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Median Arcuate Ligament Syndrome (MALS).

Locations

Essen, NW, Germany
Other Locations
Detmold, NW, Germany
Aachen, NW, Germany
St. Franziskus Hospital, Schönsteinstr. 63, Koeln, NW 50825, Germany
Berlin, BE, Germany
Bonn, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicentre, Open-Label, Randomised, Two-Arm, Parallel-Group, Superiority Study to Assess Bioavailability and Practicability of Envarsus® Compared With Advagraf® in de Novo Liver Transplant Recipients (EnGraft)
Multicentre, Open-Label, Randomised, Two-Arm, Parallel-Group, Superiority Study to Assess Bioavailability and Practicability of Envarsus® Compared With Advagraf® in de Novo Liver Transplant Recipients (EnGraft)
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2025
Intervention Type: Drug
Study Phase: Phase 4
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus
Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2024
Intervention Type: Radiation, Drug
Study Drugs: 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Carboplatin, Paclitaxel
Study Phase: Phase 3
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
View 2 Less Clinical Trials

423 Total Publications

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Neumann's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile